At least four drugs approved in 2011 - Eylea aflibercept, Incivek telaprevir, Yervoy ipilimumab and Zytiga abiraterone acetate - are anticipated to exceed $500 million in sales in 2012. Of those, Incivek has already passed $1 billion. However, demand for the HCV drug reversed course in 2012. In July 2012, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) cited two factors for the decrease in the number of HCV patients initiating Incivek treatment: doctors waiting for all-oral combination therapies; and an increase in the number of HCV clinical trials (see BioCentury, Nov. 12, 2012).

For the first nine months of 2012, Eylea sales were $561.9 million. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which launched the drug in the U.S. for wet age-related macular degeneration (AMD) in November 2011, saw its share price triple in 2012.